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Abstract
Introduction: Many patients with arthrosis have side effects produced by conventional 
treatments. These patients are candidates for pain palliation with 153Sm-EDTMP. Patients with 
cancer bone metastases usually require a bone scanning procedure using 99mTc-MDP, prior to 
treatment through 153Sm-EDTMP. This work has two aims. Firstly, to assess the use of 153Sm-
EDTMP as an alternative in bone scanning procedures in patients with bones metastases. Se-
condly, if the 1536P('703 LV XSWDNHQ E\ WKH DUWKURVLV LQMXUHG MRLQW WKHQ WKH HIÀFLHQW DQG VDIH 
use of the systemic administration of this radiopharmaceutical is evaluated for pain palliation.
Methods and materials: A non-probabilistic, of opportunity and sequential sample of 10 patients 
with arthrosis was selected, as well as, one patient with bone metastasis secondary to prostate 
cancer. in the 11 patients, bone scans were performed using both radiopharmaceuticals 99mTc-
MDP and 153Sm-EDTMP to compare image quality and uptake sites. in patients with arthrosis a 
therapeutic dose with 153Sm-EDTMP was systemically administered for pain palliation. Hemato-
ORJLF SURÀOHV ZHUH SHUIRUPHG LQ RUGHU WR DVVXUH VHFXULW\ WR WKH ERQH PDUURZ 3DLQ DQG PRWLOLW\ 
evaluations were carried out to assess the 1536P('703 DQDOJHVLF HIÀFDF\ 
Results and conclusion: The image qualities obtained with 153Sm-EDTMP are similar from the 
clinical point of view to those obtained with 99mTc-MDP. 153Sm-EDTMP is captured by joints with 
arthrosis and bone metastases. Therapeutic doses of 153Sm-EDTMP intravenously administered 
are well tolerated by the bone marrow, while an analgesic effect is present which improves 
motility and quality of life in patients with arthrosis.
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Experiencia clínica preliminar del uso sistémico de 153Sm-EDTMP como agente 
SDOLDWLYR GHO GRORU HQ OD DUWURVLV \ FRPR XQD RSFLyQ SDUD OD H[SORUDFLyQ JDPPDJUiÀFD 
ósea en pacientes con metástasis óseas
Resumen
Introducción: Muchos pacientes con artrosis tienen efectos secundarios producidos por los tra-
tamientos convencionales. Estos pacientes son candidatos para tratamiento paliativo del dolor 
con 153Sm-EDTMP. los pacientes con metástasis ósea, por lo general, requieren un rastreo utili-
zando 99mTc-MDP, antes del tratamiento paliativo con 153Sm-EDTMP. Este trabajo tiene 2 obje- 
tivos: 1) evaluar el uso de 153Sm-EDTMP como alternativa en los procedimientos de rastreo óseo 
en pacientes con metástasis ósea y, 2) si el 153Sm-EDTMP es captado en la articulación lesionada 
FRQ DUWURVLV HQWRQFHV VH HYDO~D HO XVR HÀFLHQWH \ VHJXUR GH OD DGPLQLVWUDFLyQ VLVWpPLFD GH HVWH 
radiofármaco, para la paliación del dolor por artrosis.
Métodos y materiales: Una muestra no probabilística, de oportunidad y secuencial de 10 pacientes 
con artrosis fue seleccionada, así como, un paciente con metástasis ósea secundaria a cáncer de 
próstata. En los 11 pacientes se realizaron gammagrafías óseas con los radiofármacos 99mTc-MDP y 
153Sm-EDTMP, para comparar la calidad de imagen y sitios de captación. En los pacientes con artrosis 
se administró por vía sistémica una dosis terapéutica de 153Sm-EDTMP para la paliación del dolor. Se 
UHDOL]DURQ SHUÀOHV KHPDWROyJLFRV FRQ HO ÀQ GH JDUDQWL]DU OD VHJXULGDG GH OD PpGXOD yVHD /D HYROX-
FLyQ GHO GRORU \ GH OD PRWLOLGDG VH XWLOL]y SDUD HYDOXDU OD HÀFDFLD DQDOJpVLFD 153Sm-EDTMP. 
Resultados y conclusión: la calidad de imagen obtenida en los 11 pacientes con 153Sm-EDTMP es si-
milar desde el punto de vista clínico, a las obtenidas con 99mTc-MDP. El 153Sm-EDTMP es captado por 
las articulaciones con artrosis y metástasis óseas. la dosis terapéutica de 153Sm-EDTMP administrada 
por vía intravenosa fue bien tolerada por la médula ósea en todos los pacientes, así como hubo un 
efecto analgésico, por lo que mejoró la motilidad y la calidad de vida en los pacientes con artrosis. 
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Introduction
Osteoblasts are mononucleate cells responsible for bone 
formation (osteoblastosis). Bone metastasis caused by va-
rious types of cancers (breast, prostate, lung, etc.) is one of 
the diseases of the skeletal system in which there is high 
osteoblastic activity. The effects of this disease can be pa-
lliated with the use of diphosphonates, non-hormonal 
DJHQWV ZLWK DIÀQLW\ IRU RVWHREODVWLF DFWLYLW\ VLWHV ZKLFK DFW 
as osteoblastosis inhibitors1-3. 
in nuclear medicine, diphosphonates are used both as 
diagnostic and therapeutic agents. in diagnosis, they are 
usually administered in the form of methyl diphosphonate 
labeled with 99mTc (99mTc-MDP) for routine bone scanning and 
treatment follow-up of chemotherapy and/or radiotherapy 
of bone metastases4,5. As a therapeutic agent, the ethylene-
diaminetetramethylenephosphonate labeled with 153Sm 
(153Sm-EDTMP) and the hydroxyethylidenediphosphonate la-
beled with 186re (186re-HEDP) are among the most commonly 
used. These compounds have been successfully employed 
alone or combined with other diphosphonates, in the 
treatment of secondary bone metastases of breast, lung, 
kidney and prostate cancer6-12. 
Another disease of the skeletal system, where osteoblas-
tosis is present, is the arthrosis, a degenerative joint disea-
se associated to aging. it is the most common type of 
arthropathy and one of the most disabling disorders in deve-
loped countries. it is the second leading cause of long term 
disability, following cardiovascular disease. The estimated 
annual cost in the United States is more than $33 billion, 
due to the treatment of the disease and the work absen-
teeism caused by it. Characteristic symptoms are: deep 
pain that worsens over time, morning stiffness, snapping 
and limitation of movement. The most commonly affected 
joints are the hips, knees, cervical and low lumbar verte-
EUDH SUR[LPDO DQG GLVWDO LQWHUSKDODQJHV DQG WKH ÀUVW FDU-
pal-metacarpal and tarsus-metatarsus joint1-3. As the 
histological mechanism that governs the arthrosis is similar 
to that in bone metastasis (this mechanism being the osteo-
blastosis), and the therapeutic action of the diphosphonates 
is to act on this mechanism, it is expected that if diphospho-
nates have therapeutic action on bones metastasis, they 
will have it on the arthrosis, as well. The 153Sm-EDTMP has 
been approved by the Food and Drug Administration (FDA) 
for pain palliation in bone metastasis. However, it has been 
employed, together with the 186re-HEDP for pain palliation 
LQ RWKHU ERQH GLVHDVHV VXFK DV LQÁDPPDWRU\ DUWKULWLV UH-
fractory rheumatoid arthritis and multifocal arthritis when 
conventional treatments have failed13,14. So far, there are to 
our knowledge no published works on the use of radiolabe-
led diphosphonates, specifically 153Sm-EDTMP in the 
treatment of arthrosis.
Conventional treatments for arthrosis are based on the 
administration of analgesics such as acetaminophen or non-
VWHURLGDO DQWLLQÁDPPDWRU\ DQDOJHVLF GUXJV 16$,'V 7KHVH 
drugs are toxic and cause damage to the gastric and duode-
nal mucosa. They are frequently suspended due to side 
effects and the patient motility is still compromised by 
pain. Surgery and / or prosthesis are not always an option, 
due to medical or economic reasons. it’s for those patients 
that the 153Sm-EDTMP pain palliation therapy is proposed. 
The use of this compound in the treatment of bone metasta-
ses produces pain palliation in 30% to 90% of the patients 
with an average of 65% and its effect lasts from one to 18 
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months. if similar effects are found in patients with arthro-
VLV WKHLU TXDOLW\ RI OLIH ZRXOG EH VLJQLÀFDQWO\ LPSURYHG 
On the other hand, patients who claim pain in the bones 
and have already been diagnosed with cancer, are strong 
candidates to be suffering from bone metastases. The con-
ventional procedure to follow is to perform a bone scanning 
using 99m7F0'3 DQG RQFH PHWDVWDVHV DUH FRQÀUPHG WKH SD-
lliative treatment with 153Sm-EDTMP starts about a week af-
ter. The 153Sm radionuclide is a beta-gamma emitter which 
decays with a half-life of 46.284 hours. This radionuclide 
enhances the analgesic effect of the diphosphonate because 
of its beta emission (maximum energy of 810 keV and avera-
ge of 233 keV). But it also has a gamma emission with ener-
gy of 103 keV, which could be useful for bone imaging. in 
these patients, if a bone scan is performed, using 153Sm-
EDTMP (following the same protocol 99mTc-MDP), once the 
ERQH PHWDVWDVHV GLDJQRVLV LV FRQÀUPHG D 153Sm-EDTMP the-
rapeutic dose can be immediately completed, optimizing 
treatment time and cost.
7KH DLP RI WKLV ZRUN LV WR H[SORUH WKH HIÀFLHQW DQG VDIH 
use of systemically administered 153Sm-EDTMP in two cases. 
Firstly, as a bone scanning agent for patients suspected to 
have bone metastases, prior to its use as a palliative for 
pain. Secondly, as an analgesic treatment for patients with 
arthrosis, to whom conventional treatments have not been 
effective and/or have produced undesirable side effects, 
after verifying that the compound is uptaken in the injured 
MRLQW ,Q WKH ÀUVW FDVH WKH GLDJQRVWLF HIÀFLHQF\ RI WKH FRP-
pound is evaluated, based on image quality, compared to 
the conventional 99mTc-MDP agent. in the second case, the 
palliative effect on pain and joint motility enhancement is 
assessed, while monitoring patients’ hematology to assure 
no toxicity to the bone marrow. This study was carried out 
with the knowledge and signed consent of the patients in-
volved.
Methods and materials 
Patient selection, inclusion, non-inclusion and 
exclusion criteria to the study
Patients, who participated in this study, expressed their 
agreement through a signed written consent. The research 
protocol was approved by the research and Bioethics Com-
mittee of the School of Medicine of the Autonomous Univer-
sity of the State of Mexico (Universidad Autónoma del 
Estado de México, UAEMex), and by the Scientific and 
Bioethics research Committee of the Oncology Center of 
the institute of Social Security of the State of Mexico and 
Municipalities (Centro Oncológico Estatal del Instituto de 
Seguro Social del Estado de México y Municipios, COE-iSSE-
MyM).
The patient inclusion criteria were the following: male or 
female non pregnant, of at least 55 years of age, with diag-
nosed arthrosis (joint pain and reduced motility) or, with 
suspected bone metastases. in the case of patients with ar-
throsis, their response to previous conventional treatments 
must have been unsatisfactory. 
The criteria of non-inclusion and exclusion of the study 
ZHUH KLVWRU\ RI KHUHGLWDU\ FDQFHU LQ ÀUVW GHJUHH UHODWLYHV 
(in order to decrease the probability of stochastic effects); 
additional pathologies such as diabetes, liver and kidney di-
seases as well as disorders of the urinary and reproductive 
systems; discontinuity in treatment follow-up appointments; 
dropping out of the study due to personal reasons or compli-
cations of the illness.
Sampling 
A non-probabilistic, of opportunity and sequential sample of 
10 patients (5 female and 5 male), was selected, with a 
diagnosis of arthrosis. Patients` average age was 68 years, 
median 70 years, range from 58 to 77 years and standard 
deviation of 7.3 years. in addition, a male patient of 56 
years with bone metastasis secondary to prostate cancer 
was included.
Study protocol
Bone scanning image acquisition using 99mTc-MDP and 153Sm-
EDTMP in the patient with bone metastasis and in patients 
with arthrosis
,Q RUGHU WR FRPSDUH WKH XSWDNH DQG WKH GLDJQRVWLF HIÀFLHQ-
cy through image quality, of the proposed radiopharmaceu-
tical, an activity of 740MBq of 99mTc-MDP was administered 
to each patient through one minute of intravenous infusion, 
followed by oral administration of 2,000 ml of water to fa-
cilitate elimination through urine. After 3 hours, a bone 
scan was performed, using a double detector, variable an-
gle, Siemens e.cam gamma camera, with the detectors in a 
180º angle, during 12-15 minutes. 
Two weeks later, a second set of images were acquired in 
the same patients, administering 740MBq of 53Sm-EDTMP, fo-
llowing the same protocol as for 99mTc-MDP. The bone scans 
obtained with both radiopharmaceuticals were qualitatively 
compared in order to evaluate the uptake of the 153Sm-
EDTMP.
Static images acquisition using 99mTc-MDP and 153Sm-EDTMP 
in the patient with bone metastasis and in patients with 
arthrosis
in order to quantitatively determine the activity uptake, 
three hours after administrating to each patient 740MBq of 
99mTc-MDP and 53Sm-EDTMP, respectively, a set of static ima-
ges was acquired using the same equipment as previously 
described. in the case of the metastatic patient, the images 
were of the patient’s left shoulder (where the metastasis 
was located) and of the upper third of the humerus, in order 
to consider the background activity. in the case of the pa-
tients with arthrosis, the images were of the patients’ knees 
and lower third of the femur. in both cases, the images were 
taken placing the affected area at 7 cm from the anterior 
detector and 15cm from the posterior one during 5 minutes.
Administration of the 153Sm-EDTMP therapeutic dose in pa-
tients with arthrosis
A therapeutic dose of 37MBq per kg of body weight was sys-
temically administered to the patient with arthrosis, in or-
der to reach the range of total injected activity from 2.1 to 
2.8gBq. This injection was followed by oral administration 
of 2,000 ml of water to facilitate elimination through urine. 
Presence of radioactivity in the patient’s urine was monito-
red during 6 hours, after which, the patient is discharged.
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Figure 1 Anterior and posterior bone scanning images of a patient with bone metastasis. A) Using 99mTc-MDP. B) Using 153Sm-EDTMP.
Bone marrow toxicity evaluation in patients with arthrosis
Evaluation of the bone marrow toxicity of the treatment 
was performed by hematology studies, during an 8-week 
follow-up. Five ml of peripheral blood of each patient were 
analyzed weekly, determining red blood cells, neutrophils, 
lymphocyte and platelet counts and were compared to the 
levels prior of 153Sm-EDTMP administration. Myelosuppres-
VLRQ ZDV FRQVLGHUHG ZKHQ D VLJQLÀFDQW GHFUHDVH ZDV UHJLV-
tered, in comparison with the reference levels.
Pain evaluation in patients with arthrosis
The evaluation of pain due to arthrosis was performed using 
a qualitative 10 point scale, where 0 represents no pain and 
10 the most intense pain, according to the recommenda-
tions of the American College of rheumatology15. in each 
patient, the intensity of pain before administration of the 
153Sm-EDTMP (reference level) is compared with the one af-
ter, once a week, for 7 weeks. it was considered that there 
was change in the intensity of pain when a variation of at 
least 2 points was recorded. A positive variation meant de-
terioration and a negative one, improvement. 
Motility evaluation in patients with arthrosis
in a similar manner, the evaluation of motility was perfor-
med also using a qualitative 10 points scale, where 10 re-
presents unrestricted motility. it was considered as an 
improvement, an increase of at least one point in the scale 
in comparison with the motility registered before the admi-
nistration of 153Sm-EDTMP (reference level) and as deterio-
ration, a decrease of at least one point. 
Statistical analysis in patients with arthrosis
The statistical analysis was performed with the Student’s t 
Test (for paired samples), where measurements of pain and 
hematology were taken from the same patient before 
and after the 153Sm-EDTMP application, once a week, for a 7 
week follow-up.
Results
Since 99mTc-MDP is the standard radiopharmaceutical to 
diagnose bone lesions, bone scans using both 99mTc-MDP and 
153Sm-EDTMP were carried in patients to visualize the uptake 
of these radiopharmaceuticals. Anterior and posterior bone 
scans acquired using 99mTc-MDP and 153Sm-EDTMP in the pa-
tient with bone metastasis and one patient with join arthro-
VLV DUH VKRZQ LQ ÀJXUHV 1 DQG 
in the patient with bone metastasis, similar uptakes in the 
same sites are observed with both radiopharmaceuticals, 
leading to the same diagnosis. Consequently, based on a cli-
QLFDO SRLQW RI YLHZ WKH GLDJQRVWLF ERQH VFDQQLQJ WR FRQÀUP 
the presence of bone metastases can be performed either 
with 99mTc-MDP or 153Sm-EDTMP.
The advantage of using 153Sm-EDTMP as a diagnostic agent 
can be supported by the fact that, in a patient with suspec-
ted bone metastases, the localization of those can be deter-
mined with a trace activity of 153Sm-EDTMP, and once 
FRQÀUPHG WKH DFWLYLW\ FDQ EH LPPHGLDWHO\ FRPSOHWHG WR D 
therapeutic one. in this way the bone scan with 99mTc-MDP 
would not be necessary, therefore the pain palliation 
treatment would be optimized in time and cost.
As in the case of bone metastasis, for patients with ar-
throsis, similar uptakes in the pathologic joints are also ob-
served with both radiopharmaceuticals. Therefore, 
153Sm-EDTMP can be used in the treatment of arthrosis be-
cause it is uptaken and retained in the injured joins.
in order to evaluate the uptake trend among a healthy 
knee, a knee with arthrosis, and a site with bone metasta-
ses, static images were taken using both 99mTc-MDP and 
153Sm-EDTMP. Table 1, shows the rOi/background ratios ob-
tained from the anterior and posterior static images. The 
bone metastasis site is located in the left shoulder of the 
patient. it also shows that the rOi/background ratio for 
both radiopharmaceuticals is very similar, indicating a simi-
lar trend uptake in the different regions.
A b
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in the case of the metastatic patient, the upper third of 
the humerus was considered the background value becau- 
se the metastatic region was the shoulder. For both ra-
GLRSKDUPDFHXWLFDOV WKH UHVXOWV DUH VLPLODU 7KHUH LV VLJQLÀ-
cant difference in captured activity, between background 
and both healthy knee and injured sites. Among injured si-
tes, for each radiopharmaceutical, captured activity is also 
VLJQLÀFDQWO\ GLIIHUHQW EHLQJ KLJKHU LQ WKH PHWDVWDWLF ERQH 
intermediate in the knee with arthrosis and low in the 
healthy knee. This is due to a higher osteoblastic activity in 
a joint compared to skeletal bone. 
Figure 3 shows the results obtained in the average number 
of red blood cells, neutrophils, lymphocytes and platelets, 
in the 10 patients with arthrosis after the systemic adminis-
tration of a therapeutic dose of 153Sm-EDTMP, during a 7 
weeks follow-up. 
Despite count variations shown in Figure 3 with respect to 
pre-treatment levels, after the 7 weeks period, some values 
were fully reestablished and others were stabilized with a 
WHQGHQF\ WR UHDFK QRUPDO OHYHOV 1R FOLQLFDOO\ VLJQLÀFDQW WR-
xic effect on bone marrow was observed, since none of the 
SDWLHQWV UHTXLUHG VSHFLÀF FRUUHFWLYH WKHUDSHXWLF LQWHUYHQ-
tion. 
Figure 4 shows the evolution of the average level of pain 
and motility in the 10 patients with arthrosis, during the 7 
weeks of follow-up, after completing the administered acti-
vity of 153Sm-EDTMP to the therapeutic level.
in all patients, the reduction of pain was notoriously mar-
ked and the motility was also improved. The improvement 
in motility was not as remarkable as the pain reduction but 
VXIÀFLHQW WR VKRZ HIIHFWLYH DQDOJHVLF HIIHFW RI 153Sm-EDTMP 
in arthrosis.
Discussion
The similar behavior of 153Sm-EDTMP and 99mTc-MDP in bone 
lesions in patients with metastases or arthrosis is explained 
by the fact that the carrier molecule in both radiopharma-
ceuticals is a diphosphonate, which is preferably captured 
in the sites of higher osteoblastic activity. For this reason 
the images obtained with both radiopharmaceuticals are 
very similar and lead to the same diagnosis. However, given 
Table 1 regions of interest (rOi) / background ratios in three different locations: healthy knee, knee with arthrosis and bone 
metastasis shoulder, in anterior (IA) and posterior (IP) views 
rOi/Background ratio
99mTc 153Sm
location IA IP IA IP
Healthy knee (n=9) 1.64 ± 0.01 1.39 ± 0.01 1.41 ± 0.01 1.64 ± 0.02
Knee with arthrosis (n=11) 2.14 ± 0.01 1.91 ± 0.01 2.47 ± 0.01 2.82 ± 0.02
Bone metastasis shoulder (n=1) 4.38 ± 0.01 2.17 ± 0.01 3.95 ± 0.01 2.37 ± 0.01
Figure 2 Anterior and posterior bone scanning images of a patient with arthrosis. A) Using 99mTc-MDP. B) Using 153Sm-EDTMP.
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the high radiation dose absorbed in the bone marrow due to 
740 MBq of 153Sm-EDTMP for bone scanning (1.54 mgy/MBq), 
this procedure is not recommended for routine exploratory 
purposes. it is only recommended for patients already diag-
nosed with cancer and who also complain of bone pain, and 
therefore suspected to have bone metastases. These pa-
tients are candidates to pain palliation treatment with 
153Sm-EDTMP therapeutic doses (> 740 MBq).
On the use of 153Sm-EDTMP for pain palliation in patients 
with arthrosis, an important matter to take into account is 
the absorbed dose. The range of total injected activity 
in this work was from 2.1 to 2.8 gBq. in a work reported by 
Wick et al.16, the incidence of leukemia and other malignant 
diseases was investigated after 10 weekly injections of 
about 1 MBq of 224ra each, in humans. This radionuclide is 
deposited, as well as 153Sm-EDTMP, in bone. it has a longer 
half-life (T1/2 = 3.66 d) than 153Sm and decays to radioactive 
nuclides, unlike 153Sm who decays to stable 153Eu. The cumu-
ODWLYH ŞGRVH WR WKH PDUURZ GXH WR 224ra is 0.56 gy which 
represents 11.2 Sv, and the one due to 153Sm is (1.54 mgy/
MBq * 2800, MBq = 4.3 gy) 4.3 Sv. The value of 2800 MBq is 
the maximum activity of 153Sm-EDTMP injected in our study 
for arthrosis pain palliation. Wick et al.16, reported that 
“the time-dependent cumulative hazard function is nearly 
proportional to the expected cumulative hazard until about 
30 years after 224Ra treatment”. The expected cumulative 
hazard was determined from a population not exposed to 
the 224ra treatment. They also found that for exposed pa-
tients, the probability of leukemia and myeloid leukemia 
LQFLGHQFH LV DSSUR[LPDWHO\  ²  WLPHV DQG DERXW ÀYH WLPHV 
higher respectively, 35 – 45 years after the first 224ra 
treatment.
Although the treatment with 224ra is more aggressive to 
bone marrow that that with 153Sm-EDTMP (224ra equivalent 
dose is 11.4 Sv vs. 4.3 Sv for 153Sm), let’s assume that the 
probabilities for cumulative hazard and leukemia are 
the same. The average age of patients with arthrosis in this 
study was 68 years. Despite of the low number of patients, 
this age is very representative of patients with advanced 
arthrosis who present disabling pain and had a number of 
unsuccessful previous treatments. As stated previously, pa-
tients with hereditary cancer history, diabetes, liver and 
kidney diseases as well as disorders of the urinary and re-
productive systems were excluded from this study. By 2010, 
life expectancy in Mexico was 77.8 and 73.1 years for wo-
men and men respectively. if these patients are going to 
suffer from leukemia of any other malignant disease as a 
consequence of the treatment with 153Sm-EDTMP 30 years 
later, they would be by then 98 years old. it is most likely 
that they would have died before that age due to any other 
condition, while at the present time; their quality of life is 
greatly improved because of the pain palliation.
in fact, the hematology values reported in this work are in 
very good agreement with a previous reported study where 
153Sm-EDTMP has been systemically administered for pain 
palliation in refractory rheumatoid arthritis13. in that study, 
Mikuls et al. injected an activity of 37 MBq/Kg, which is 
exactly the same activity administered in this work. They 
found that bone marrow suppression was both mild and 
transient. in our case, 7 weeks post-injection there was an 
overall decrease of about 5% in the number of erythrocytes. 
Erythrocytes show an initial decline of approximately 
200,000 cells during the first two weeks post-treatment, 
with almost full recovery by fourth week. From week 4 to 
week 5 the same reduction in about 200,000 cells is obser-
YHG DQG WKH UHDFKHG QXPEHU LV VWDELOL]HG 6LJQLÀFDQW VWD-
tistical differences (p<0.05) relative to the pre-treatment 
values, (Student’s t Test for paired samples) were found in 
all weeks excepting week 4. in Mikuls et al. work13, the ove-
rall reduction of erythrocytes was 6%.
The overall reduction in the number of neutrophils is 
DERXW 0 6LQFH WKH ÀUVW ZHHN WKH WHQGHQF\ LV WR GHFUHDVH 
over time until week 6, where the value is stabilized. This 
0 RI GHFUHDVH PHDQV D UHGXFWLRQ RI 100 FHOOV 6LJQLÀ-
cant statistical differences (p<0.05) relative to the pre-
treatment values (Student’s t Test for paired samples), were 
found in all weeks. in Mikuls et al. work13, the overall reduc-
tion of neutrophils was also 40%.
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Figure 3 normalized hematology values in 10 patients with 
arthrosis, during 7 weeks of follow-up, after 153Sm-EDTMP ad-
ministration.
Figure 4 Average level of pain and motility in 10 patients with 
arthrosis, during the 7 weeks of follow-up, after 153Sm-EDTMP 
administration.
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The lymphocytic cells show a maximum decrease of 
0 LQ WKH ÀUVW ZHHN SRVWLQMHFWLRQ 7KLV GHFUHDVH FRUUHV-
ponds, in absolute numbers, to approximately 400 cells and 
LV VWDWLVWLFDOO\ VLJQLÀFDQW p<0.05). From the third week on, 
the tendency is to recover the pre-treatment value. By 
week 6 post-treatment, the pre-treatment number of lym-
phocytes was fully recovered and exceeded in about 5%. 
Finally, platelet count shows a progressive reduction du-
ring 4 weeks post-injection reaching a maximum decrease 
of 35% by week 4. From this week on, the tendency was to 
reach a full recovery. By week 7 post-injection the platelet 
value was about 92% on the pre-treatment level. in absolute 
numbers this means a reduction from 220.000 to 146,000 
platelets by week 4 post-injection and a recovery to 202,000 
E\ ZHHN  6WDWLVWLFDOO\ VLJQLÀFDQW GLIIHUHQFHV ZHUH REVHU-
ved from week 2 to 6 post-injection. in Mikuls et al. work13, 
the overall reduction of platelets was 42% reaching this 
maximum reduction value also at week 4 post-injection.
The variations found in this work on the hematological 
SURÀOH DUH QRW RQO\ LQ JRRG DJUHHPHQW ZLWK 0LNXOV HW DO 
work13, but also with other results reported in the literature 
such as the palliative effect of 153Sm-EDTPM on breast can-
cer bone metastasis pain, resistant to opioid medication12. 
Despite the high dose received by the bone marrow from 
the 153Sm decay process, the hematological values obtained 
in this work indicates, as in the case of the referred works, 
that the systemic administration of 37 MBq/Kg is well tole-
rated.
in the assessment of the pain, the pre-treatment value of 
7 point had a rapid decrease during the 3 weeks post-injec-
tion to reach a value of 4 points. During the following weeks 
WKH SDLQ UHGXFWLRQ ZDV PRUH JUDGXDO UHDFKLQJ D ÀQDO DQG 
VWDEOH YDOXH RI  SRLQWV 6WDWLVWLFDO GLIIHUHQFHV ZHUH VLJQLÀ-
cant (p00 VWDUWLQJ IURP WKH ÀUVW SRVWLQMHFWLRQ ZHHN ,Q 
the case of joint motility, an average improvement of 3 
points in the respective scale was also observed. These re-
sults were consistent in all patients, demonstrating the 
analgesic properties of 153Sm-EDTMP intravenously adminis-
tered, in accordance with its previously known analgesic 
properties in radiation synovectomy7-9. These results are 
also in good agreement with Palmedo et al.14 where 186re-
HEDP was systemically injected to patients with polyarthri-
tis. They found that a single injection led to an improvement 
of the disease reducing both pain and inflammation in 
joints. 
Arthrosis can be a very disabling disease for adults who 
are still in working active age. This may become in a serious 
problem given the level of absenteeism that it causes and 
the limited quality of life. One alternative for those pa-
tients where conventional treatments have failed and refu-
se synovectomy is the systemic administration of 
153Sm-EDTMP. A detailed analysis of the patient´s medical 
history is required. if the patient is candidate for the 
treatment, a therapeutic dose of the radiopharmaceutical is 
administered which is well tolerated by the bone marrow.
Conclusions
Bone scanning using 740 MBq of 153Sm-EDTMP and 99mTc-MDP 
were carried out in 10 patients with arthrosis and one pa-
tient with bone metastases. Both radiopharmaceuticals 
were administered systemically. images obtained show that 
both radiopharmaceuticals are uptaken in the same injured 
sites. images produced by 153Sm-EDTMP are similar to those 
obtained with the conventional protocol with 99mTc-MDP 
from a clinical point of view. Therefore, in an effort to opti-
mize in time and cost the pain palliation treatment in pa-
tients with suspected bone metastases, secondary to 
D FRQÀUPHG SULPDU\ FDQFHU D WUDFH DFWLYLW\ RI 153Sm-EDTMP 
could be used as a diagnostic agent, prior to the therapeutic 
dose. Additionally, given that 153Sm-EDTPM is captured by 
joints injured by arthrosis, a therapeutic activity of 2.1 to 
2.8 gBq of 153Sm-EDTPM was administered to patients with 
arthrosis whom conventional treatments had previously fai-
led. This administration from the dosimetric point of view 
was well tolerated, and from the clinical one has analgesic 
effect.
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